Loading…
Based on limited metadata, IceRx received an FDA Warning Letter on October 9, 2018 regarding drug products. Without access to the full letter text or subject line, the specific nature of the violations cannot be determined from the available information. The warning falls under FDA's drug product regulatory authority, though the specific issuing office is not identified in this metadata. To understand the particular compliance issues cited, the complete Warning Letter would need to be reviewed.